Eli Lilly and Novo Nordisk, the two companies that dominate the global market for GLP-1 weight loss and diabetes drugs, are each deploying artificial intelligence...
When is a breakthrough diabetes and weight loss treatment problematic? Never — except perhaps when it drastically changes the multibillion-dollar weight loss industry, causing ripple effects...